The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Open accessAbstract
The β-haemoglobinopathies, such as sickle cell disease and β-thalassaemia, are caused by mutations in the β-globin (HBB) gene and affect millions of people worldwide. Ex vivo gene correction in patient-derived haematopoietic stem cells followed by autologous transplantation could be used to cure β-haemoglobinopathies. Here we present a CRISPR/Cas9 gene-editing system that combines Cas9 ribonucleoproteins and adeno-associated viral vector delivery of a homologous donor to achieve homologous recombination at the HBB gene in haematopoietic stem cells. Notably, we devise an enrichment model to purify a population of haematopoietic stem and progenitor cells with more than 90% targeted integration. We also show efficient correction of the Glu6Val mutation responsible for sickle cell disease by using patient-derived stem and progenitor cells that, after differentiation into erythrocytes, express adult β-globin (HbA) messenger RNA, which confirms intact transcriptional regulation of edited HBB alleles. Collectively, these preclinical studies outline a CRISPR-based methodology for targeting haematopoietic stem cells by homologous recombination at the HBB locus to advance the development of next-generation therapies for β-haemoglobinopathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accordingly, several reports have shown efficient Glu6Val correction in SCD-HSPCs, although correction efficiency can sometimes be linked with off-target INDELs in the same edited population15,16,45,46.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“RNP delivery results in an initially high level of the genome editing machinery followed by rapid decay, leading to a “fast on, fast off” strategy that results in highly efficient editing while minimizing OTEs13–19.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AAV6 homologous donor DNA templates are an efficient way to deliver donor templates for sensitive primary immune cells, including HSPCs and T-Cells15,35–40.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies have shown that disease-causing genetic errors can be corrected using CRISPR/Cas9 in long-term engrafting HSPCs that are preserved in downstream effector lineages15,16,24,25.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Major progress in delivering to 44 and handling HPSCs has resulted in formidable efficiencies of mutation correction or mitigation 18,45-47 that are expected to be curative.”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [45]
Experimental — accuracy not yet measured
In the citing paper
“Furthermore, CRISPR/Cas9 system holds tremendous promise for gene therapy [46–51]. It can correct causal mutations in the original genome and rescue the disease phenotypes of monogenic disorders permanently, which currently represents the most translatable field in CRISPR/Cas9-mediated disease therapy.”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Easy quantitative assessment of genome editing by sequence trace decomposition
Brinkman, E. K., Chen, T., Amendola, M., & van Steensel, B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku936 · Cited by 2,390
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Gene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-Leukemia
Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L., Ponzoni, M., Rossini, S., Mavilio, F., Traversari, C., et al. (1997) · Science · doi:10.1126/science.276.5319.1719 · Cited by 1,158
Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells
Hendel, A., Bak, R. O., Clark, J. T., Kennedy, A. B., Ryan, D. E., Roy, S., Steinfeld, I., Lunstad, B. D., Kaiser, R. J., Wilkens, A. B., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3290 · Cited by 1,090
Self-citationIsolation of a candidate human hematopoietic stem-cell population.
Baum, C. M., Weissman, I. L., Tsukamoto, A. S., Buckle, A., & Péault, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2804 · Cited by 1,084
Hematopoietic stem cell: self‐renewal versus differentiation
Seita, J., & Weissman, I. L. (2010) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.86 · Cited by 997
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–864 of 864
Gene Editing Approaches for Haematological Disorders
Ferrari, S., & Canarutto, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00053-6
Aplicaciones clínicas de la herramienta CRISPR-Cas
Vaglio-Cedeño, C., Rodriguez, E. J. R., & Morales, F. (2023) · Acta Médica Costarricense · doi:10.51481/amc.v65i3.1268
Exploring Healthcare Utilization Events towards PalliativeTherapy in Sickle Cell Anemia
T.Neema, N., & Dil, S. (2024) · International Journal of Innovative Science and Research Technology (IJISRT) · doi:10.38124/ijisrt/ijisrt24jun222
Zhu, B., Zhou, J., He, H. J., Liao, Y., & Li, Q. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35530
Applications of CRISPR technology
Du, Z. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23865-9.00003-4
Lentiviral vector-mediated gene therapy for hematopoietic stem cells
Uchida, N. (2024) · Drug Delivery System · doi:10.2745/dds.39.267
Self-citationApplication and Prospect of Gene Editing Technology in Immunotherapy
Zhao, Y. (2025) · Highlights in Science Engineering and Technology · doi:10.54097/814b9h72
The future of genome studies of complex human and plant disease
Desai, S. A., Patel, V. P., Nagare, S. D., Pagare, N. B., & More, M. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-31554-1.00014-5
della Volpe, L., Vacca, R., & Micco, R. D. (2025) · STAR Protocols · doi:10.1016/j.xpro.2025.103722
Gene therapy: A progress in childhood disease
Dewase, D. S., & Narwade, A. R. (2025) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2025.31.1.0138
Gummakonda, R. R. (2025) · International Journal of Science and Research (IJSR) · doi:10.21275/sr25630213206
Deng, Y., Tang, Z., Yin, H., Su, L., Liao, H., Xie, H., Yu, L., & Chen, Z. (2025) · Microchemical Journal · doi:10.1016/j.microc.2025.114808
Novel strategies to expand and engineer hematopoietic stem cells
Klein, B. R., Blake, A., Rashmil, R., & Desai, A. B. (2025) · Stem Cells · doi:10.1093/stmcls/sxaf065
Samanta, A., Pan, P., Payra, S. K., & Bhattacharyya, N. (2025) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/3424
Ayuba, S. A., Bashar, F., & Abbas, A. Y. (2025) · International Journal of Epigenetics · doi:10.3892/ije.2025.29 · Cited by 2
Ashok, K. R., Ellango, R., Rajendran, V., Bhargava, C. N., Pavithran, S., Dhawane, Y., Manamohan, M., Jha, G. K., & Asokan, R. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148735
CRISPR/Cas9: the future of human gene editing
Zulkifli, N. D., Sani, S. B. M., Wong, C. H., Mahadzan, M., Suhimi, M. H. A., Zulkifli, N., & Das, K. T. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33947-9.00009-8
Molecular mastery: Harnessing DNA technology for disease prevention
Dornadula, G., Ramakrishna, C., Shaik, S. B., Meriga, P. K., Chintha, L., Gurugari, Y., D., K., Shaik, S. F., & Cheong, S. H. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101976
Additional file 1 of Burden of Mendelian disorders in a large Middle Eastern biobank
Aamer, W., Al-Maraghi, A., Syed, N., Gandhi, G. D., ALIYEV, E. E., Al-Kurbi, A. A., Al-Saei, O., Kohailan, M., Krishnamoorthy, N., Palaniswamy, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25560873
Additional file 2 of Burden of Mendelian disorders in a large Middle Eastern biobank
Aamer, W., Al-Maraghi, A., Syed, N., Gandhi, G. D., ALIYEV, E. E., Al-Kurbi, A. A., Al-Saei, O., Kohailan, M., Krishnamoorthy, N., Palaniswamy, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25560900
Potentiality of advanced nanomaterial based on microorganisms for regenerative medicine
Ritu, Gulia, S., Singh, S., Majhi, K., Panchal, P., Das, A., & Chandra, P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-31526-8.00003-0 · Cited by 1
Naseem, A., Vetharoy, W., Whittaker, T. E., Zinghirino, F., Ghosh, R., Gómez‐Castañeda, E., Ali, H.-J., Cipriani, C., Montini, E., Thrasher, A. J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.08.698401
Gene-Editing-Based Approaches for Curing Sickle Cell Disease
Park, S. H., Karsenty, C. L., Prasca-Chamorro, D., Moyo, B., Yoo, B., & Bao, G. (2026) · Springer eBooks · doi:10.1007/978-3-032-12532-3_8
Therapeutic Genome Engineering for the Treatment of Sickle Cell Disease
Leonard, A. K., Sharma, A., Chao, F.-Y., & Yen, J. S. (2026) · Springer eBooks · doi:10.1007/978-3-032-12532-3_9
Bibliometric Insights into CRISPR-Cas9 Research Targeting Human Disease Pathology
Sweileh, M. W. (2026) · SAGE Open · doi:10.1177/21582440261415669
TFU72 is a novel and potent DNA-PKcs inhibitor for enhancing homology-directed repair gene editingPreprint
Selvaraj, S., Schmiderer, L., Lamberth, J., Fuchß, T., Ekman, F. K., Russkamp, N. F., & Porteus, M. H. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.10.710954
Self-citationCRISPR-Cas9: Genome Engineering and Future Vaccine Applications
Madhi, M., & Gholizadeh, P. (2026) · Molecular Biotechnology · doi:10.1007/s12033-026-01563-4
New therapeutic strategies for the treatment of β-hemoglobinopathies
Weber, L. (2018) · theses.fr (ABES) · doi:10.70675/09314463zdfd1z46b4z9c0cz32c6c2c5ccc2
Li, Z., Wang, X., Liu, J., Janssen, J. M., Hoeben, R. C., & Gonçalves, M. A. F. V. (2026) · Trends in biotechnology · doi:10.1016/j.tibtech.2026.01.006
Drépanocytose et polymorphismes génétiques : épidémiologie, prédiction de gravité et stress-oxydant
Gueye, F. (2019) · theses.fr (ABES) · doi:10.70675/ba1cd2c2z7fe6z4d0dzb10fz91439ce84eb9
Génotoxicité des systèmes CRISPR-Cas9.
Cullot, G. (2019) · theses.fr (ABES) · doi:10.70675/cb1809e4zaafbz4fc1z89e9zeb0e5fd69275
Base editing approaches for the treatment of β-hemoglobinopathies
Antoniou, P. (2021) · theses.fr (ABES) · doi:10.70675/c4dddb32zf8aez4bc3z8cf8zce9a4e808265
Ex vivo gene therapy for β-hemoglobinpathies and metabolic disorders
Laurent, M. (2023) · theses.fr (ABES) · doi:10.70675/ba5c585dzaa79z48d2z9f40zfee1cdd49d32
Development of gene therapy approaches to ß-hemoglobinopathies
Chalumeau, A. (2023) · theses.fr (ABES) · doi:10.70675/7fc1b037zbffbz4005z9109zd81aa6f38a83
Base editing approaches for the treatment of ß-hemoglobinopathies
Hardouin, G. (2022) · theses.fr (ABES) · doi:10.70675/593cd291z9d0ez45a6z82cdz64ffb2e65ff8
CRISPR-Cas9-based strategies for enhanced targeted integration
Lacombe, L. (2024) · theses.fr (ABES) · doi:10.70675/9c9d279dz512az4b72z8322zea205cef9b67
Kuo, C. Y., Harrington, S., Campo-Fernández, B., Wyman, S. K., Wu, X., Zhang, R., Espinoza, A., Silva, B. J. D. A., Sanchez, J. M., Fitz‐Gibbon, S. T., et al. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-026-05010-8
Sanchez‐Petitto, G., & de Lima, M. J. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1014678
Robust CRISPR-Cas Protein Identification Using Max-Margin Regularized Transformer Models
Nammi, B., Madugula, S. S., Pujar, P., Jayasinghe‐Arachchige, V. M., Liu, J., & Wang, S. (2026) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbbio.2026.3693528
The Molecular Pathology of Non-Malignant Haematological Disease
Blann, A. D., & Dunn, R. G. (2026) · British Journal of Biomedical Science · doi:10.3389/bjbs.2026.14743
The Journey of Gene Therapy in Sickle Cell Disease: How Molecular Advances Meet Clinical Care
Tardif, M., Saby, M., Forté, S., & Pincez, T. (2026) · Cells · doi:10.3390/cells15100939
CRISPR and Fanzor in sickle cell disease: current progress and future prospects
Humoudi, A. Y. A., Alotaibi, A. G., Alosaimi, N. F., Alshalani, A., Alqahtani, S. D., Alsaab, S. M., Almutiri, B. J., & Albariqi, M. M. H. (2026) · Frontiers in Genome Editing · doi:10.3389/fgeed.2026.1774014
Gao, Z.-Y., Shen, T.-L., Cheng, C.-Y., Sun, Y., Zhang, L., Zhang, J.-P., & Zhang, X.-B. (2026) · Human Gene Therapy · doi:10.1177/10430342261453040
Font, L. F., Jin, D., Figg, J., Francis, C. P., Long-James, K., Drake, J., Reid, A., Love, C., McDonald, B., Hilferty, D., et al. (2026) · Journal of Translational Research · doi:10.1080/29947448.2026.2660423
Wang, W., Zhou, M., Ji, T., Jiang, Q., Zhao, J. J., Xu, Z., Liu, R., Luo, Y., Han, F., Cong, L., et al. (2026) · Cell Reports Methods · doi:10.1016/j.crmeth.2026.101474
Hara, H., Uosaki, H., Nakahara, F., Inoue, M., & Hanazono, Y. (2026) · Genes to Cells · doi:10.1111/gtc.70129
Ravendran, S., Fammé, S., Noer, M. G., Skov, T. W., Mikkelsen, N. S., Schneller, J. L., Dorset, S. R., Wolff, J. H., Møller, A. M. J., Haslund, D., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201787
Self-citationGene Therapy and CRISPR-based Intervention in Sickle Cell Anemia
Dere, V. V., Patil, S. S., Kale, A. Y., & Otari, K. V. (2026) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/3515
Chen, H., Kadzioch, N. P., Gapp, M., Yang, H.-H., Ruhle, A., Villamizar, J. M., Fuchs, T., Schmacke, N. A., Hornung, V., Speck, R. F., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.05.741689
Chen, J. J., Lawanprasert, A., Kleinhenz, A. L. W., Namala, M. G. D., Chu, D., Tang, Y., Lindarto, V., Launspach, M., Lee, D., Wu, H., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.04.741347
Engineering Hematopoietic Immunity: The Next Evolution of Transplantation and Cellular Therapy
Morabito, F., Martino, E. A., Bruzzese, A., Amodio, N., Vigna, E., & Gentile, M. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70290
Intervenciones genéticas en embriones: Revisión sistemática
Cheng, S., Kolangui, T., Mendoza, V., & Zhu, A. (2026) · Conducta Científica · doi:10.65050/rcc.v9n2a2
Hammoud, M. S., & Hanna, R. (2026) · JCO Oncology Practice · doi:10.1200/op-26-00479
From Delivery to Design: Site-Specific Genome Engineering for Next-Generation CAR T-Cell Therapy
Aldahshan, H., Al-Hubaysh, A., Alrabiah, D. K., Alturki, M., Alkharji, R. R., Lin, S., Aldughaim, M. S., & Albugami, R. R. (2026) · Biomedicines · doi:10.3390/biomedicines14091925
Biologic Therapies for Alleviating Neurodegeneration in Lysosomal Storage Diseases
Qiu, L., Ungerbäck, J., Bennett, E., & Bak, R. O. (2026) · BioDrugs · doi:10.1007/s40259-026-00804-x
Self-citationSung, W., Li, T., & Takeoka, S. (2026) · Frontiers in Genome Editing · doi:10.3389/fgeed.2026.1888079
DeWitt, M. A., Campo-Fernández, B., Roy, S., Kleinhenz, A. L. W., Davila, A., Lennon, M. L., Vu, J. T., Krishnappa, N., Said, S., Tseng, C.-H., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.09.020
Xu, M., Zhang, X., Wang, K., Gong, Y., Chen, W., Che, D., Wang, Q., Zhou, H., Chen, G., & Zhang, K. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108983
MN•CS•IO System: Cross‐Species Study for HBB Function in High‐Altitude Hypoxia Adaptation
Hui, W., Mao, L., Li, B., Kang, H., Tang, Z., Chen, S., Yang, H., Qiao, Y., Ding, H., Wang, Y., et al. (2026) · Advanced Science · doi:10.1002/advs.78002
Sickle cell disease-specific barriers to in vivo hematopoietic stem cell gene therapy
Choi, R., & Sheehan, V. (2026) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.09.003
Electroporation-Mediated Delivery of CRISPR Technologies for Liver Disease Cell Therapy and Modeling
Cottle, R. N. (2026) · Springer eBooks · doi:10.1007/978-3-319-26779-1_289-1
Prime editing of human hematopoietic stem cells for correction of GATA2 deficiency
Wolff, J. H., Skov, T. W., Dorset, S. R., Sjelborg, J., Ravendran, S., Revenfeld, A. L., Haslund, D., Møller, A. M. J., Holm, M., Thomsen, M. K., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aec7031
Self-citationWang, S., Wang, X., Shang, M., Wu, K., Zhang, M., & Huang, W. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.16.759525
Metadata
- Authors
- Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., Uchida, N., Hendel, A., Narla, A., Majeti, R., Weinberg, K. I., & Porteus, M. H.
- Affiliations
- Stanford University (US)
- Institute for Stem Cell Biology and Regenerative Medicine (US)
- Stanford Medicine (US)
- Corresponding author
- Porteus, Matthew H.
- ORCID
- Venue
- Nature
- Published
- 2016-11-07
- Volume
- 539
- Issue
- 7629
- Pages
- 384-389
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5898607
- OpenAlex
- W2547418311
- Semantic Scholar
- 91eb4c33902b14df9b2974a4ce8dc6e3c3a02125
- Cited by
- 864
- References
- 50
- Citations by year
- 2026: 45 · 2025: 75 · 2024: 80 · 2023: 93 · 2022: 76 · 2021: 120 · 2020: 93 · 2019: 90 · 2018: 99 · 2017: 89 · 2016: 4
- FWCI
- 48.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (5r01ai120766-02, R01-AI120766)
- National Eye Institute (PN2EY018244)
- National Institute of General Medical Sciences (T32GM007266)
- National Institute of Allergy and Infectious Diseases (R01-AI120766, R01AI097320)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Keywords
- CRISPR/Cas9 genome editing, beta-globin gene, hematopoietic stem cells, sickle cell disease, beta-thalassemia, homologous recombination, adeno-associated virus vectors, Cas9 ribonucleoprotein, autologous transplantation, reporter genes
- MeSH terms
- Gene Editing, Dependovirus, Alleles, Anemia, Sickle Cell, Animals, Cell Differentiation, Cell Separation, Erythrocytes, Female, Flow Cytometry, Hematopoietic Stem Cells, Humans, Microspheres, Mutation, RNA, Messenger, Genetic Therapy, Mice, SCID, Mice, Inbred NOD, beta-Thalassemia, Genes, Reporter, Gene Targeting, Antigens, CD34, Cell Lineage, beta-Globins, Magnets, Homologous Recombination, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
